C4 Therapeutics, Inc. (CCCC)
After hours:
| Previous close | 6.80 |
| Open | 6.85 |
| Bid | 6.11 x 100 |
| Ask | 6.17 x 700 |
| Day's range | 6.15 - 6.93 |
| 52-week range | 1.06 - 11.88 |
| Volume | |
| Avg. volume | 2,224,553 |
| Market cap | 423.844M |
| Beta (5Y monthly) | 3.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.67 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.75 |
- GuruFocus.com
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations
Performance Analysis and Future Outlook Amidst Financial Adjustments
GlobeNewswireC4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 0
- GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company’s common stock to one new employee (the “Inducement Grant
